Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
•
Supportive Care
•
Immune-related adverse events
•
Neurology
•
Endocrinology
•
General Endocrinology
How do you manage suspected hypophysitis/hypopituitarism as an immune-related adverse event?
What lab tests/imaging do you obtain and how do you initially treat?
Related Questions
Would you favor oral bisphosphonates over intravenous formulations for patients with hormone sensitive prostate cancer and androgen deprivation therapy (ADT) related osteopenia?
How would you manage a patient with FIGO stage IIIB endometrial carcinoma who developed significant back pain with Carboplatin/Paclitaxel cycle 1, which worsened during cycle 2?
What treatments, after appropriate dose reductions/delays, do you offer for patients with oxaliplatin-induced cold allodynia/dysesthesia?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
How would you advise medical oncologists who recommend checkpoint inhibitors for a patient with baseline type 1 diabetes?
Should GLP-1 agonists be held during chemotherapy?
How do 24-hour urine creatinine levels affect your interpretation of 24-hour urinary calcium or cortisol studies?
When utilizing KN-A18 protocol, how do you best address symptoms of colitis/cystitis?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
When do you recommend adjuvant trastuzumab for completely resected uterine cancer and for how long do you give it?